171 related articles for article (PubMed ID: 29746922)
1. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?
Gallo M; Ruggeri RM; Muscogiuri G; Pizza G; Faggiano A; Colao A;
Cancer Treat Rev; 2018 Jun; 67():1-9. PubMed ID: 29746922
[TBL] [Abstract][Full Text] [Related]
2. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
Singhi AD; Klimstra DS
Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
[TBL] [Abstract][Full Text] [Related]
4. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F
Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290
[TBL] [Abstract][Full Text] [Related]
5. High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour.
Gong Y; Fan Z; Zhang P; Qian Y; Huang Q; Deng S; Luo G; Cheng H; Jin K; Ni Q; Yu X; Liu C
Endocrine; 2021 Feb; 71(2):494-501. PubMed ID: 32862321
[TBL] [Abstract][Full Text] [Related]
6. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
7. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
8. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
[TBL] [Abstract][Full Text] [Related]
12. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
[TBL] [Abstract][Full Text] [Related]
13. Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation.
de Vries C; Konukiewitz B; Weichert W; Klöppel G; Aupperle-Lellbach H; Steiger K
J Comp Pathol; 2020 Nov; 181():73-85. PubMed ID: 33288156
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease.
Viúdez A; De Jesus-Acosta A; Carvalho FL; Vera R; Martín-Algarra S; Ramírez N
Crit Rev Oncol Hematol; 2016 May; 101():193-206. PubMed ID: 27021395
[TBL] [Abstract][Full Text] [Related]
15. Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour.
Johnson A; Wright JP; Zhao Z; Komaya T; Parikh A; Merchant N; Shi C
Histopathology; 2015 Jan; 66(2):225-33. PubMed ID: 25307987
[TBL] [Abstract][Full Text] [Related]
16. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract][Full Text] [Related]
17. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
18. Advancements in pancreatic neuroendocrine tumors.
Sadaria MR; Hruban RH; Edil BH
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):477-90. PubMed ID: 23899286
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment.
Tanno L; Naheed S; Dunbar J; Tod J; Lopez MA; Taylor J; Machado M; Green B; Ashton-Key M; Chee SJ; Wood O; Pearce NW; Thomas GJ; Friedmann PS; Cave J; Ottensmeier CH
Neuroendocrinology; 2022; 112(4):370-383. PubMed ID: 34157710
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
Marini F; Giusti F; Brandi ML
Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
